{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:14:03Z","timestamp":1768504443787,"version":"3.49.0"},"posted":{"date-parts":[[2023,3,15]]},"group-title":"Bioengineering","reference-count":59,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,3,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Although high-dose, multi-agent chemotherapy has improved leukemia survival rates in recent years, treatment outcomes remain poor in high-risk subsets, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in infants. Development of new, more effective therapies for these patients is therefore an urgent, unmet clinical need. To address this challenge, we developed a nanoscale combination drug formulation that exploits ectopic expression of MERTK tyrosine kinase and dependency on BCL-2 family proteins for leukemia cell survival in pediatric AML and\n                  <jats:italic>MLL-<\/jats:italic>\n                  rearranged precursor B-cell ALL (infant ALL). In a novel, high-throughput combination drug screen, the MERTK\/FLT3 inhibitor MRX-2843 synergized with venetoclax and other BCL-2 family protein inhibitors to reduce AML cell density\n                  <jats:italic>in vitro<\/jats:italic>\n                  . Neural network models based on drug exposure and target gene expression were used to identify a classifier predictive of drug synergy in AML. To maximize the therapeutic potential of these findings, we developed a combination monovalent liposomal drug formulation that maintains ratiometric drug synergy in cell-free assays and following intracellular delivery. The translational potential of these nanoscale drug formulations was confirmed in a genotypically diverse set of primary AML patient samples and both the magnitude and frequency of synergistic responses were not only maintained but were improved following drug formulation. Together, these findings demonstrate a systematic, generalizable approach to combination drug screening, formulation, and development that maximizes therapeutic potential, was effectively applied to develop a novel nanoscale combination therapy for treatment of AML, and could be extended to other drug combinations or diseases in the future.\n                <\/jats:p>","DOI":"10.1101\/2023.03.13.531236","type":"posted-content","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T13:17:20Z","timestamp":1678886240000},"source":"Crossref","is-referenced-by-count":0,"title":["Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-6728","authenticated-orcid":false,"given":"James M","family":"Kelvin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-5301","authenticated-orcid":false,"given":"Juhi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aashis","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Qui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-3565","authenticated-orcid":false,"given":"Lacey A","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1187-1066","authenticated-orcid":false,"given":"Samuel G","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan J","family":"Summers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Costanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biaggio","family":"Uricoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan T","family":"Jui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2362-7979","authenticated-orcid":false,"given":"Haian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7457-9006","authenticated-orcid":false,"given":"Deborah","family":"DeRyckere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-6900","authenticated-orcid":false,"given":"Douglas K","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4954-8443","authenticated-orcid":false,"given":"Erik C","family":"Dreaden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"25","key":"2023031712550409000_2023.03.13.531236v1.1","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study","volume":"37","year":"2019","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2023031712550409000_2023.03.13.531236v1.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"2023031712550409000_2023.03.13.531236v1.3","doi-asserted-by":"crossref","unstructured":"Choi KY , Correa S , Min J , Li J , Roy S , Laccetti KH , et al. Binary Targeting of siRNA to Hematologic Cancer Cells In Vivo using Layer-by-Layer Nanoparticles. Advanced functional materials. 2019;29(20).","DOI":"10.1002\/adfm.201900018"},{"key":"2023031712550409000_2023.03.13.531236v1.4","doi-asserted-by":"publisher","DOI":"10.1021\/nn4047925"},{"key":"2023031712550409000_2023.03.13.531236v1.5","doi-asserted-by":"crossref","unstructured":"Detappe A , Nguyen HV , Jiang Y , Agius MP , Wang W , Mathieu C , et al. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nature nanotechnology. 2023.","DOI":"10.1038\/s41565-022-01310-1"},{"issue":"10","key":"2023031712550409000_2023.03.13.531236v1.6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acscombsci.0c00081","article-title":"Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia","volume":"22","year":"2020","journal-title":"ACS combinatorial science"},{"issue":"19","key":"2023031712550409000_2023.03.13.531236v1.7","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1158\/1078-0432.CCR-15-0013","article-title":"Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle","volume":"21","year":"2015","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"6","key":"2023031712550409000_2023.03.13.531236v1.8","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1021\/acsnano.6b00320","article-title":"Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer","volume":"10","year":"2016","journal-title":"ACS nano"},{"key":"2023031712550409000_2023.03.13.531236v1.9","doi-asserted-by":"crossref","unstructured":"Houdaihed L , Evans JC , Allen C. In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus. Cancers (Basel). 2019;11(6).","DOI":"10.3390\/cancers11060752"},{"issue":"1","key":"2023031712550409000_2023.03.13.531236v1.10","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1038\/s41467-020-17958-z","article-title":"Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints","volume":"11","year":"2020","journal-title":"Nat Commun"},{"key":"2023031712550409000_2023.03.13.531236v1.11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062630"},{"key":"2023031712550409000_2023.03.13.531236v1.12","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2005261"},{"key":"2023031712550409000_2023.03.13.531236v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/nature03794"},{"issue":"5","key":"2023031712550409000_2023.03.13.531236v1.14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","year":"2013","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"19","key":"2023031712550409000_2023.03.13.531236v1.15","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1200\/JCO.19.03306","article-title":"Phase I\/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children\u2019s Oncology Group","volume":"38","year":"2020","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"2023031712550409000_2023.03.13.531236v1.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425033"},{"key":"2023031712550409000_2023.03.13.531236v1.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707414"},{"issue":"1","key":"2023031712550409000_2023.03.13.531236v1.18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/hematology.2022000359","article-title":"Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy","volume":"2022","year":"2022","journal-title":"Hematology American Society of Hematology Education Program"},{"issue":"2","key":"2023031712550409000_2023.03.13.531236v1.19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17474086.2018.1420474","article-title":"A concise review of BCL-2 inhibition in acute myeloid leukemia","volume":"11","year":"2018","journal-title":"Expert review of hematology"},{"key":"2023031712550409000_2023.03.13.531236v1.20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313"},{"key":"2023031712550409000_2023.03.13.531236v1.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"2023031712550409000_2023.03.13.531236v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"issue":"1","key":"2023031712550409000_2023.03.13.531236v1.23","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia","volume":"6","year":"2016","journal-title":"Scientific Reports"},{"key":"2023031712550409000_2023.03.13.531236v1.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-828269"},{"issue":"3","key":"2023031712550409000_2023.03.13.531236v1.25","first-page":"e85630","article-title":"The MERTK\/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia","volume":"1","year":"2016","journal-title":"JCI Insight"},{"key":"2023031712550409000_2023.03.13.531236v1.26","doi-asserted-by":"publisher","DOI":"10.1021\/jm500749d"},{"key":"2023031712550409000_2023.03.13.531236v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0357-9"},{"key":"2023031712550409000_2023.03.13.531236v1.28","doi-asserted-by":"crossref","unstructured":"Qiu KY , Liao XY , Liu Y , Huang K , Li Y , Fang JP , et al. Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3\/ITD allelic ratios. NATURE COMMUNICATIONS. 2022;13(1).","DOI":"10.1038\/s41467-022-31489-9"},{"key":"2023031712550409000_2023.03.13.531236v1.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782292"},{"key":"2023031712550409000_2023.03.13.531236v1.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"issue":"1-2","key":"2023031712550409000_2023.03.13.531236v1.31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11010-016-2775-1","article-title":"Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies","volume":"420","year":"2016","journal-title":"MOLECULAR AND CELLULAR BIOCHEMISTRY"},{"issue":"2","key":"2023031712550409000_2023.03.13.531236v1.32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","year":"2019","journal-title":"Best practice & research Clinical haematology"},{"key":"2023031712550409000_2023.03.13.531236v1.33","first-page":"1348","article-title":"FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models","volume":"130","year":"2017","journal-title":"Blood"},{"key":"2023031712550409000_2023.03.13.531236v1.34","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.40"},{"key":"2023031712550409000_2023.03.13.531236v1.35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478156"},{"key":"2023031712550409000_2023.03.13.531236v1.36","doi-asserted-by":"crossref","unstructured":"Huey MG , Minson KA , Earp HS , DeRyckere D , Graham DK . Targeting the TAM Receptors in Leukemia. Cancers (Basel). 2016;8(11).","DOI":"10.3390\/cancers8110101"},{"key":"2023031712550409000_2023.03.13.531236v1.37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112086200"},{"key":"2023031712550409000_2023.03.13.531236v1.38","doi-asserted-by":"crossref","first-page":"107577","DOI":"10.1016\/j.pharmthera.2020.107577","article-title":"MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system","volume":"213","year":"2020","journal-title":"Pharmacology & therapeutics"},{"key":"2023031712550409000_2023.03.13.531236v1.39","unstructured":"Inc. Si . JMP(R) 16 Documentation Library. 2020-2021."},{"key":"2023031712550409000_2023.03.13.531236v1.40","doi-asserted-by":"crossref","first-page":"122176","DOI":"10.1016\/j.jchromb.2020.122176","article-title":"Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies","volume":"1152","year":"2020","journal-title":"Journal of chromatography B, Analytical technologies in the biomedical and life sciences"},{"issue":"1","key":"2023031712550409000_2023.03.13.531236v1.41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40543-020-00252-4","article-title":"LC-Q-TOF-MS driven identification of potential degradation impurities of venetoclax, mechanistic explanation on degradation pathway and establishment of a quantitative analytical assay method","volume":"11","year":"2020","journal-title":"Journal of Analytical Science and Technology"},{"key":"2023031712550409000_2023.03.13.531236v1.42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-459313"},{"issue":"9","key":"2023031712550409000_2023.03.13.531236v1.43","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.18632\/oncotarget.3156","article-title":"Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia","volume":"6","year":"2015","journal-title":"Oncotarget"},{"key":"2023031712550409000_2023.03.13.531236v1.44","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3389\/fphar.2019.01384","article-title":"Additive Dose Response Models: Defining Synergy","volume":"10","year":"2019","journal-title":"Frontiers in pharmacology"},{"key":"2023031712550409000_2023.03.13.531236v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/nature11003"},{"issue":"3","key":"2023031712550409000_2023.03.13.531236v1.46","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","year":"2015","journal-title":"Pharmacology research & perspectives"},{"issue":"9","key":"2023031712550409000_2023.03.13.531236v1.47","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia","volume":"25","year":"2019","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"2023031712550409000_2023.03.13.531236v1.48","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/s12885-015-1582-5","article-title":"Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim","volume":"15","year":"2015","journal-title":"BMC cancer"},{"key":"2023031712550409000_2023.03.13.531236v1.49","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2658"},{"issue":"24","key":"2023031712550409000_2023.03.13.531236v1.50","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2023031712550409000_2023.03.13.531236v1.51","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3324\/haematol.2021.278369","article-title":"AXL\/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3 -ITD acute myeloid leukemia","volume":"107","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2023031712550409000_2023.03.13.531236v1.52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-020-00973-4","article-title":"Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia","volume":"13","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"2023031712550409000_2023.03.13.531236v1.53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2019.12.023","article-title":"The role of liposomes in clinical nanomedicine development. What now? Now what?","volume":"318","year":"2020","journal-title":"Journal of Controlled Release"},{"issue":"4","key":"2023031712550409000_2023.03.13.531236v1.54","doi-asserted-by":"crossref","first-page":"2000297","DOI":"10.1002\/ejlt.202000297","article-title":"The Use of Phospholipids to Make Pharmaceutical Form Line Extensions","volume":"123","year":"2021","journal-title":"European Journal of Lipid Science and Technology"},{"key":"2023031712550409000_2023.03.13.531236v1.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.01.015"},{"key":"2023031712550409000_2023.03.13.531236v1.56","doi-asserted-by":"crossref","first-page":"102275","DOI":"10.1016\/j.nano.2020.102275","article-title":"Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals","volume":"30","year":"2020","journal-title":"Nanomedicine : nanotechnology, biology, and medicine"},{"key":"2023031712550409000_2023.03.13.531236v1.57","doi-asserted-by":"crossref","first-page":"113851","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","year":"2021","journal-title":"Advanced drug delivery reviews"},{"key":"2023031712550409000_2023.03.13.531236v1.58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-266742"},{"issue":"6","key":"2023031712550409000_2023.03.13.531236v1.59","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/2643-3230.BCD-22-0011","article-title":"Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine","volume":"3","year":"2022","journal-title":"Blood cancer discovery"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.03.13.531236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:24:07Z","timestamp":1768451047000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.03.13.531236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1101\/2023.03.13.531236","relation":{},"subject":[],"published":{"date-parts":[[2023,3,15]]},"subtype":"preprint"}}